论文期刊

取消

高级检索

检索历史清除

首页> Theranostics> SGLT2 inhibitor dapagliflozin reduces endothelial dysfunction and microvascular damage during cardiac ischemia/reperfusion injury through normalizing the XO-SERCA2-CaMKII-coffilin pathways.

SGLT2 inhibitor dapagliflozin reduces endothelial dysfunction and microvascular damage during cardiac ischemia/reperfusion injury through normalizing the XO-SERCA2-CaMKII-coffilin pathways.

导出 OA

翻译打印收藏纠错

作者： Li,Ma ^[1] ; Rongjun,Zou ^[1] ; Wanting,Shi ^[2] ; Na,Zhou ^[1] ; Shaoxian,Chen ^[3] ; Hao,Zhou ^[4] ; Xinxin,Chen ^[1] ; Yueheng,Wu ^[3]

作者单位： Guangdong Provincial Key Laboratory of Research in Structural Birth Defect Disease, Heart Center, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou, China. ^[1] Department of Paediatrics, Guangdong Provincial Key Laboratory of Research in Structural Birth Defect Disease, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou 510623, China. ^[2] Guangdong Cardiovascular Institute, Guangdong Provincial Key Laboratory of South China Structural Heart Disease, Guangdong Provincial People's Hospital & Guangdong Academy of Medical Sciences, School of Medicine, South China University of Technology, Guangzhou, China. ^[3] Senior Department of Cardiology, The Sixth Medical Center of People's Liberation Army General Hospital, Beijing, China. ^[4]

关键词 CaMKII Dapagliflozin SERCA2 XO cardiac ischemia/reperfusion injury cofilin microvascular dysfunction

主题词肌动蛋白解聚因子类(Actin Depolymerizing Factors);动物(Animals);二苯甲基化合物(Benzhydryl Compounds);钙(Calcium);钙-钙调素依赖性蛋白激酶2型(Calcium-Calmodulin-Dependent Protein Kinase Type 2);内皮细胞(Endothelial Cells);葡糖苷类(Glucosides);人类(Humans);缺血(Ischemia);小鼠(Mice);心肌再灌注损伤(Myocardial Reperfusion Injury);黄嘌呤氧化酶(Xanthine Oxidase)

DOI 10.7150/thno.75121

PMID 35836807

发布时间 2023-01-11

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览1

Theranostics

Theranostics

2022年12卷11期

5034-5050页

相似文献

中文期刊
外文期刊
学位论文
会议论文

特别提示：本网站仅提供医学学术资源服务，不销售任何药品和器械，有关药品和器械的销售信息，请查阅其他网站。

客服热线：4000-115-888 转3 (周一至周五：8:00至17:00)
|
客服邮箱：yiyao@wanfangdata.com.cn

违法和不良信息举报电话：4000-115-888，举报邮箱：problem@wanfangdata.com.cn，举报专区

官方微信

万方医学小程序

关于我们网站地图知识产权

北京万方数据股份有限公司

万方数据电子出版社

京ICP证010071号

京公网安备11010802020237号

京ICP备08100800号-1

违法和不良信息举报电话：4000-115-888，举报邮箱：problem@wanfangdata.com.cn，举报专区

new翻译充值订阅收藏移动端

官方微信

万方医学小程序

调查问卷